In the face of intensified pressures we delivered a good performance in 2011 and took difficult decisions to ensure the future success of AstraZeneca.
Louis Schweitzer Chairman Dear Shareholder I write to you at the end of a year in which  to shareholders $m 2011 2010 2009 Dividends 3,764 3,361 2,977 based pharmaceutical companies faced a tough 1 2 Share repurchases 6,015 2,604 marketplace and operating environment.
Against this Total 9,779 5,965 2,977 challenging background, disciplined execution of our strategy delivered a good performance.
Our strong cash Dividend for 2011 $ Pence SEK Payment date flow supported a significant increase in cash distributions First interim dividend 0.85 51.9 5.33 12 September 2011 Second interim dividend 1.95 123.6 13.21 19 March 2012 to shareholders and continued investment to drive future Total 2.80 175.5 18.54 growth and value.
These conditions also provided the 1 Share repurchases in 2011, net of proceeds from the issue of share capital equal to backdrop to the annual review by your Board of our $409 million, were $5,606 million.
2 Share repurchases in 2010, net of proceeds from the issue of share capital equal to business strategy which remains to be a focused, $494 million, were $2,110 million.
integrated, innovation-driven, global, prescriptionbased biopharmaceutical business.
6 Chairmans Statement AstraZeneca Annual Report and Form 20-F Information 2011 Overview Chairmans Statement I would like to take this opportunity to review AstraZenecas financial For us, that means a continued focus on ensuring we drive: performance in 2011 and the decisions we took to ensure we continue to deliver sustainable value for you.
world class productivity in R&D increased external collaboration Financial performance a global orientation, reflecting the growth in Emerging Markets stronger customer orientation, particularly towards payers Group sales in 2011 were down 2% at CER to $33,591 million 2010: $33,269 million and reported operating profit was up 10% operational efficiency with a flexible cost base.
at $12,795 million 2010: $11,494 million, which included the gain on the sale of Astra Tech.
Performance for the year reflected strong Our 2011 review highlighted the ongoing need for a substantial improvement in R&D productivity if we are to sustain acceptable double digit sales growth for Crestor, Seroquel XR and Symbicort.
It was also impacted by government pricing interventions and generic returns to shareholders.
We are therefore planning to accelerate our R&D strategy.
We intend to take a new approach to Neuroscience, competition, which combined to reduce revenue by some $3 billion.
Revenue in the US was down 2%, as was revenue in markets outside closing our existing research centres and creating a new virtual innovative medicines unit for our R&D in this challenging field.
the US: revenue was down 11% in Western Europe, up 4% in Established ROW and up 10% in Emerging Markets.
We also plan to reshape our other R&D global functions to better support a more focused portfolio and create a simpler organisation Reported earnings per share for the full year were up 29% at with greater flexibility in all functional areas.
$7.33 2010: $5.60, which also included the non-taxable gain of $1.08 from the Astra Tech sale.
Our effective tax rate also In his Chief Executive Officers Review on the following pages, David Brennan outlines the steps we took in 2011 to secure our future benefited from an adjustment in respect of prior periods following the announcement in March 2011 that HM Revenue & Customs in the business success.
David also emphasises that how we do business is as important as what we do.
We need to continue to work with UK and the US Internal Revenue Service had agreed the terms of an Advance Pricing Agreement regarding transfer pricing arrangements integrity and to high ethical standards if we are to deliver on our promise of bringing benefits to patients, creating sustainable value for AstraZenecas US business.
for shareholders and contributing to economic and social welfare.
In this regard, the Board has an important role to play in setting high A challenging marketplace The world pharmaceutical market grew by 4.5% in 2011 and the standards and monitoring performance.
fundamentals of the industry remain strong.
First, the world population continues to increase and age: it passed the seven billion mark in Outlook We continue to plan on the basis that revenue will be in the range 2011, while the number of people over 65 in 2030 is estimated to be almost one billion, double the 2005 figure.
Secondly, we are seeing of $28-34 billion a year over the 2010-14 period, as revenue growth from key franchises that retain exclusivity and continued growth in the emergence of expanding numbers of patients in new markets who can access our medicines for the first time.
Thirdly, there remains Emerging Markets are pressured by the loss of market exclusivity on a number of products.
However, based on the evolution of the base considerable unmet medical need.
Chronic diseases are on the increase, not only in wealthy countries but also in middle income and, case assumptions since 2010, such as the downward pressure on revenue from government interventions, revenue for the remainder increasingly, lower income countries.
For example, some 346 million people around the world have diabetes while 24 million are affected of the period is likely to be in the lower half of the range.
Finally, advances in science and technology promise the continued delivery of new medicines that can make a real Returns to shareholders In recognition of the Groups strong balance sheet and sustainable difference to patient health.
significant cash flow, and the Boards confidence in the strategic direction and long-term prospects for the business, we announced, Yet, while the fundamentals remain strong, the challenges facing the industry have been unprecedented in recent years.
Patents on some in conjunction with the full year 2009 results, the adoption of a progressive dividend policy, intending to maintain or grow the of the worlds most successful innovative medicines are starting to expire and we face increasing competition from generic alternatives.
After providing for business investment, funding the progressive dividend policy and meeting our debt service Additionally, the need to improve R&D productivity and the number of product launches remains a critical challenge for the whole sector.
obligations, the Board will also keep under review the opportunity to return cash in excess of these requirements to shareholders Around the world, rising healthcare costs, coupled with the difficult through periodic share repurchases.
economic climate and continued austerity measures being implemented by governments, have resulted in pressure on prices.
The Board has recommended a second interim dividend of $1.95, a 5% increase over the second interim dividend awarded in 2010.
This includes pricing interventions in many countries.
The regulatory landscape is changing, becoming more global and more complex.
This brings the dividend for the full year to $2.80 175.5 pence, SEK 18.54, an increase of 10% from 2010.
In 2011, cash distributions to It is no longer enough for new medicines to be safe and effective.
Health authorities increasingly require additional information regarding shareholders through dividends totalled $3,764 million and net share repurchases totalled $5,606 million.
a medicines comparative clinical and cost effectiveness.
Appreciation Our strategic response It was with these challenges in mind that your Board undertook its In the face of intensified pressures we delivered a good performance in 2011 and took difficult decisions to ensure the future success strategy review process in 2011.
We are confident that long-term growth in demand for innovative biopharmaceuticals will remain of AstraZeneca.
None of this would have been possible without the leadership of David Brennan and the other members of his strong.
We believe there continue to be opportunities to create value for those who invest in pharmaceutical innovation, and that executive team.
My thanks, and those of the whole Board, go to them and all our employees for their effort in working to deliver on AstraZeneca has the skills and capabilities to take advantage of these opportunities and turn them into long-term value through the research, our promise.
development and marketing of our medicines.
We also recognise that the industry is going through a period of fundamental change as it seeks to overcome the serious challenges we face.
Louis Schweitzer Chairman AstraZeneca Annual Report and Form 20-F Information 2011 Chairmans Statement 7
